X. Meng

Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials

J. Olin, C. Sadowsky, M. Farlow, 2009, International journal of clinical practice.

Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.

R. Bermel, D. Kantor, R. Hashmonay, 2015, Multiple sclerosis and related disorders.

A Randomized, Double-Blind, Multicenter, Open Phase IV Clinical Trial to Evaluate The Efficacy and Safety of A Chinese Patent Medicine Combined With Mesalazine for Ulcerative Colitis

Hong Shen, Lei Zhu, Pei-min Feng, 2020 .

Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease

J. Cummings, D. Velting, G. Alva, 2015, International journal of clinical practice.

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS).

F. Barkhof, L. Kappos, H. Hartung, 2014, Multiple sclerosis and related disorders.

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease

P. Doraiswamy, M. Farlow, X. Meng, 2011, Dementia and Geriatric Cognitive Disorders Extra.

Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer’s disease

J. Olin, G. Grossberg, X. Meng, 2011, International journal of clinical practice.